CTRI/2022/05/042905
Not yet recruiting
未知
inear Clinical Study to Evaluate the Anti-Inflammatory and Beneficial Effects ofβ-1, 3-1, 6-Glucan, N-163 on DMD Patients - N-163
MediNippon Health Care Private Limited MD0 sites0 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- MediNippon Health Care Private Limited MD
- Status
- Not yet recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Subject who diagnosed with DMD
- •2\. Male subject of age in between 3 years to 30 years
- •3\. Subjects and legally authorized representative for vulnerable subjects must be willing to participate in the study and provide a written informed consent
- •4\. Subject willing to and able to comply with the protocol
Exclusion Criteria
- •1\. Subject participated in another clinical trial in the last 30 days.
- •2\. Subjects and legally authorized representative for vulnerable subjects who has not given informed consent for this study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Clinical study to evaluate the efficacy, pharmacokinetics and safety of immunoglobulin intravenous (human) 10% (NewGam) in patients with primary immunodeficiency diseasesPrimary immunodeficiency diseases (PID)Haematological DisordersCommon variable immunodeficiencyISRCTN05425999Octapharma AG (Switzerland)50
Not yet recruiting
Phase 3
Effect of Ayurvedic Eye Treatment in Diabetic RetinopathyHealth Condition 1: H36- Retinal disorders in diseases classified elsewhereCTRI/2022/10/046903ational Institute of Ayurveda Jaipur
Active, not recruiting
Phase 3
Clinical study to assess how well wilate works in the regular treatment of young children with severe von Willebrand diseaseISRCTN11217735Octapharma (Austria)12
Recruiting
Not Applicable
Clinical pharmacology study to evaluate the pharmacokinetics, safety and efficacy of multi-targetted tyrosine kinase inhibitor regorafenib in Japanese patients with advanced colorectal cancer.Colorectal CancerJPRN-UMIN000013939Showa University School of Medicine100
Recruiting
Not Applicable
Clinical pharmacy services to improve management outcomes of Chronic Kidney Disease of uncertain etiology patients undergoing hemodialysisChronic Kidney Disease of uncertain etiologySLCTR/2018/011ational Science Foundation